Mavyret (Glecaprevir, an HCV NS3/4A protease inhibitor/Pibrentasvir, an HCV NS5A inhibitor) is a potent drug for patients with HCV genotypes 2–6 without cirrhosis or with mild cirrhosis [5], whereas Zepatier and Grazoprevir are highly effective for HCV genotypes including 1a, 1b and 4 [6]. Here, KRAS is linked to Cirrhosis.